Lead the path to a commitment to continuous growth in the sector and improving patient outcomes
Chelmsford, Massachusetts & Novi, Michigan, Germany & Tokyo, Dusseldorf, April 24, 2025 – (Business Wire) – Asahi Kasei has appointed Kenshinomiya, president of Asahi Kasei Life Sciences, as the leader of the healthcare sector as the successor to Richard Packer. Under Shinomiya, Kasei's Heshi healthcare sector will further its global presence with its portfolio of pharmaceuticals, life sciences and critical care products and services.
Shinomiya, who served as Vice President of Strategy at Zoll Medical Corporation from 2016 to 2017, became head of the bioprocess division of Asahi Kasei Medical in April 2019 and President of Asahi Kasei Medical in April 2025. With its operations focused on products and services that support the manufacture of pharmaceuticals, the life sciences business has grown globally by identifying market needs and business opportunities within the pharmaceutical industry. Under Shinomiya's leadership, Life Science Business has successfully expanded from the Basic Planova™ Virus Removal Filters through the addition of the Biological Contract Development Agency (CDMO) business of Bionova Scientific in the US, as well as the Contract Research Institute (CRO) testing service.
Asahi Kasei's healthcare sector has been dramatically globalized since 2012 when Zoll Medical Corporation acquired its US-based business platform, a life-saving platform. Since then, the healthcare sector has accelerated its growth strategy as a diverse global healthcare company by accurately identifying market needs, making aggressive investments including M&A, and moving to the US in 2023.
Under the new leadership, the healthcare sector will continue to implement long-term strategies to grow its pharmaceutical, lifestyle science and critical care businesses. Leading on its mission to “improve and save patients' lives,” the sector is committed to providing innovative treatments and medical devices that address unmet medical needs and contribute to improving patient outcomes around the world. This targets operating profit of 150 billion yen in 2030 and will serve as the main growth driver for the Kasei Asahi Kasei Group.
“For over a century, the Asako Kasei Group has created unique business models that leverage creativity and innovation to deliver outstanding products and services to the world,” says Kenshinomiya, leader of Asahi Kasei's healthcare sector. “Our healthcare business exemplifies the unique ability of shallow salmon to effectively integrate the sophisticated and efficient management approaches gained through global acquisition. By moving forward, we will further evolve based on our mixed international outlook as we continue to lead the growth and globalization of the shallow salmon group.”
The story continues
